Scientific Name: Asciminib
Brand Name: Scemblix
Company Owner: Not Available
Mechanism Of Action In most patients with chronic myeloid leukemia (CML) ,
Description of the Drug: Asciminib is an inhibitor of ABL/BCR-ABL1 tyrosine kinase for the treatment of patients with Philadelphia chromosome-positive CML, including those with the T315I mutation.
Protein Data Bank:
Source: DrugBank Online – Retrieved 2023-01-23 from